Lexeo Therapeutics (NASDAQ:LXEO) Issues Earnings Results

Lexeo Therapeutics (NASDAQ:LXEO) released its earnings results on Wednesday. The company reported ($0.30) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.30), FiscalAI reports.

Lexeo Therapeutics Price Performance

Shares of LXEO stock traded up $0.22 during trading hours on Wednesday, hitting $5.00. The stock had a trading volume of 877,513 shares, compared to its average volume of 950,138. The stock’s 50 day moving average is $4.63 and its 200 day moving average is $5.67. Lexeo Therapeutics has a twelve month low of $3.99 and a twelve month high of $10.99. The firm has a market capitalization of $392.61 million, a PE ratio of -3.45 and a beta of 1.46.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. Chardan Capital upgraded Lexeo Therapeutics to a “strong-buy” rating in a research note on Tuesday, July 28th. JPMorgan Chase & Co. lowered their price target on shares of Lexeo Therapeutics from $12.00 to $9.00 and set an “overweight” rating for the company in a report on Thursday, June 25th. Wall Street Zen raised shares of Lexeo Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. Finally, Weiss Ratings downgraded shares of Lexeo Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, July 30th. Two analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $18.75.

Insider Buying and Selling at Lexeo Therapeutics

In other Lexeo Therapeutics news, CEO Richard Nolan Townsend sold 25,947 shares of Lexeo Therapeutics stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $4.48, for a total value of $116,242.56. Following the transaction, the chief executive officer directly owned 377,817 shares in the company, valued at approximately $1,692,620.16. The trade was a 6.43% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Narinder Pal Bhalla sold 22,306 shares of the stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $4.42, for a total transaction of $98,592.52. Following the sale, the insider owned 82,194 shares of the company’s stock, valued at $363,297.48. This trade represents a 21.35% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 62,204 shares of company stock worth $280,089 over the last three months. 2.00% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Lexeo Therapeutics

A number of institutional investors have recently added to or reduced their stakes in LXEO. RA Capital Management L.P. acquired a new stake in shares of Lexeo Therapeutics in the 4th quarter valued at approximately $49,650,000. Paradigm Biocapital Advisors LP acquired a new position in Lexeo Therapeutics during the fourth quarter worth $47,299,000. Vestal Point Capital LP raised its position in Lexeo Therapeutics by 37.7% in the fourth quarter. Vestal Point Capital LP now owns 4,475,000 shares of the company’s stock worth $44,437,000 after acquiring an additional 1,225,000 shares in the last quarter. Balyasny Asset Management L.P. purchased a new position in Lexeo Therapeutics in the second quarter worth $16,117,000. Finally, Citadel Advisors LLC lifted its holdings in Lexeo Therapeutics by 3.1% in the third quarter. Citadel Advisors LLC now owns 3,719,043 shares of the company’s stock valued at $24,694,000 after acquiring an additional 111,076 shares during the period. Hedge funds and other institutional investors own 60.67% of the company’s stock.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.